 |
 |
| Verisante's "Aura" probe, shown here, is based on the same Raman spectroscopy platform as the "Core", and has been tested for a variety of cancer screening applications. The Charing Cross Hospital trial will be the first to use Raman during brain surgery. Credit: Verisante Technology. |
| © 2024 SPIE Europe |
|
